Mizuho Securities Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Sarepta Therapeutics, with a price target of $31.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Ear covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Arcutis Biotherapeutics, and uniQure. According to TipRanks, Ear has an average return of 0.7% and a 37.36% success rate on recommended stocks.

In addition to Mizuho Securities, Sarepta Therapeutics also received a Buy from Wedbush’s Yun Zhong in a report issued on March 2. However, yesterday, Piper Sandler maintained a Hold rating on Sarepta Therapeutics (NASDAQ: SRPT).

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $442.93 million and a GAAP net loss of $282.85 million. In comparison, last year the company earned a revenue of $658.41 million and had a net profit of $159.05 million

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Most recently, in December 2025, Ian Michael Estepan, the COO of SRPT sold 13,187.00 shares for a total of $294,201.97.